Squarepoint’s Liminatus Pharma LIMN Stock Holding History

Squarepoint’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,403	Closed	-$17.4K	–	5048
2025 Q3	$17.4K	Buy	+10,403	New	+$44.9K	﹤0.01%	4293

Other funds holding LIMN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Squarepoint's LIMN Position: Q4 2025 in Review

Squarepoint sold out of Liminatus Pharma (LIMN) in Q4 2025, closing a stake of 10,403 shares — an estimated $17.4K sold.

Squarepoint first reported a position in LIMN in Q3 2025 and held it in 1 quarter. The position peaked at $17.4K in Q3 2025. 12 funds tracked by Wall St. Rank hold LIMN as of Q4 2025.

Squarepoint reported no remaining Liminatus Pharma position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 10,403 Liminatus Pharma shares in Q4 2025, an estimated $17.4K.
Squarepoint first reported a position in Liminatus Pharma in Q3 2025 and held it in 1 quarter.
Squarepoint's Liminatus Pharma position peaked at $17.4K in Q3 2025.
12 funds tracked by Wall St. Rank held Liminatus Pharma as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.